EP2139327A4 - Method for treating cb2 receptor mediated pain - Google Patents

Method for treating cb2 receptor mediated pain

Info

Publication number
EP2139327A4
EP2139327A4 EP08730822A EP08730822A EP2139327A4 EP 2139327 A4 EP2139327 A4 EP 2139327A4 EP 08730822 A EP08730822 A EP 08730822A EP 08730822 A EP08730822 A EP 08730822A EP 2139327 A4 EP2139327 A4 EP 2139327A4
Authority
EP
European Patent Office
Prior art keywords
treating
receptor mediated
mediated pain
pain
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08730822A
Other languages
German (de)
French (fr)
Other versions
EP2139327A1 (en
Inventor
Mingde Xia
Christopher M Flores
Mark J Macielag
Kevin Paul Pavlick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2139327(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP2139327A1 publication Critical patent/EP2139327A1/en
Publication of EP2139327A4 publication Critical patent/EP2139327A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP08730822A 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain Withdrawn EP2139327A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21
PCT/US2008/055102 WO2008115672A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (2)

Publication Number Publication Date
EP2139327A1 EP2139327A1 (en) 2010-01-06
EP2139327A4 true EP2139327A4 (en) 2011-06-15

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08730822A Withdrawn EP2139327A4 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Country Status (13)

Country Link
EP (1) EP2139327A4 (en)
JP (1) JP2010522182A (en)
KR (1) KR20090120500A (en)
CN (1) CN101677555A (en)
AR (1) AR065801A1 (en)
AU (1) AU2008229265A1 (en)
CA (1) CA2681384A1 (en)
CL (1) CL2008000817A1 (en)
MX (1) MX2009010164A (en)
PE (1) PE20090551A1 (en)
TW (1) TW200904414A (en)
UY (1) UY30974A1 (en)
WO (1) WO2008115672A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
WO2013005168A2 (en) 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066135A2 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
WO2006030124A1 (en) * 2004-09-13 2006-03-23 Sanofi-Aventis Condensed pyrazole derivatives, preparation method thereof and therapeutic use of same
WO2007044215A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica, N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
WO2009023292A1 (en) * 2007-03-20 2009-02-19 Janssen Pharmaceutica N.V. Hexahydro-cyclooctyl pyrazole cannabinoid modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066135A2 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
WO2006030124A1 (en) * 2004-09-13 2006-03-23 Sanofi-Aventis Condensed pyrazole derivatives, preparation method thereof and therapeutic use of same
WO2007044215A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica, N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
WO2009023292A1 (en) * 2007-03-20 2009-02-19 Janssen Pharmaceutica N.V. Hexahydro-cyclooctyl pyrazole cannabinoid modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUTIERREZ T ET AL: "Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.", BRITISH JOURNAL OF PHARMACOLOGY JAN 2007 LNKD- PUBMED:17160008, vol. 150, no. 2, January 2007 (2007-01-01), pages 153 - 163, XP002634954, ISSN: 0007-1188 *
IBRAHIM MOHAB M ET AL: "CB2 cannabinoid receptor mediation of antinociception.", PAIN MAY 2006 LNKD- PUBMED:16563625, vol. 122, no. 1-2, May 2006 (2006-05-01), pages 36 - 42, XP002634953, ISSN: 1872-6623 *
See also references of WO2008115672A1 *

Also Published As

Publication number Publication date
TW200904414A (en) 2009-02-01
UY30974A1 (en) 2008-09-30
JP2010522182A (en) 2010-07-01
EP2139327A1 (en) 2010-01-06
AU2008229265A1 (en) 2008-09-25
KR20090120500A (en) 2009-11-24
PE20090551A1 (en) 2009-05-16
AR065801A1 (en) 2009-07-01
MX2009010164A (en) 2009-10-12
CA2681384A1 (en) 2008-09-25
WO2008115672A1 (en) 2008-09-25
CL2008000817A1 (en) 2008-09-26
CN101677555A (en) 2010-03-24

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating dependence
GB2445465B (en) Process for waste treatment
EP2195067A4 (en) Apparatus for treating bone
EP2249752C0 (en) Apparatus for treating obesity
GB0714363D0 (en) Treatment apparatus
EP2083857A4 (en) Methods for treating mica-related disorders
EP2175873A4 (en) Treatment for anxiety
EP2176459A4 (en) Apparatus for treating clothing
GB0724836D0 (en) Waste control apparatus
EP2219449A4 (en) Methods for treating visceral pain
HK1203305A1 (en) Methods for treating psoriasis
EP2272472A4 (en) Excrement treating apparatus
HK1139856A1 (en) Methods for treating acute pain
EP2331097A4 (en) Methods for treating cns disorders
PL2376597T3 (en) Method for treating waste
GB0718684D0 (en) Treatment method
HK1110262A1 (en) Waste treatment method
EP2182884A4 (en) Treatment apparatus
EP2139327A4 (en) Method for treating cb2 receptor mediated pain
IL202261A0 (en) Method for pain control
EP2139326A4 (en) Method for treating cb2 receptor mediated pain
EP2209488A4 (en) Fgf9-related methods for treating anxiety
IL207906A0 (en) Treatment for ocular-related disorders
GB0722274D0 (en) New therapeutic method
AP2010005225A0 (en) Process for treating sulphatecontaining effluent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/415 20060101ALI20110504BHEP

Ipc: A61K 31/416 20060101ALI20110504BHEP

Ipc: A01N 43/56 20060101AFI20081010BHEP

Ipc: A61P 29/00 20060101ALI20110504BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110811